Resistance to therapy continues to be a prominent issue in oncology, constraining treatment efficacy and leading to cancer relapse. The workshop "Therapy Resistance" centers on gaining insight into the mechanisms of resistance, clinical relevance, and ways to bypass it in contemporary cancer management.".
Tumor cells may escape therapy by genetic mutation, epigenetic modification, drug efflux, activation of bypass signaling pathways, or adaptation to the tumor microenvironment. All these mechanisms decrease the efficacy of chemotherapy, targeted therapy, immunotherapy, and radiation, frequently leading to disease relapse. Understanding these pathways is important for developing successful interventions and enhancing patient outcomes.
The session discusses strategies to combat resistance, such as combination therapies, adaptive treatment schedules, and new targeted agents. Real-time monitoring and biomarker-guided approaches, e.g., liquid biopsy and molecular profiling, facilitate early identification of resistant tumor populations and enable timely adjustment of treatment schedules. New studies emphasize prevention of resistance development by early treatment and modulation of the tumor microenvironment.
Participants will learn about the biology, clinical issues, and novel solutions for resistance to therapy. This session highlights the need for tackling resistance to improve the efficacy of treatment, extend survival, and facilitate personalized, precision oncology strategies for patients with relapsed or refractory cancers.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
